Universidade Federal do Paraná, Curitiba, PR, Brazil.
Rev Paul Pediatr. 2022 Jul 6;41:e2021197. doi: 10.1590/1984-0462/2023/41/2021197. eCollection 2022.
The aim of this current report was to present a critical review of the use of cannabidiol (CBD) in the treatment of refractory epilepsies in the pediatric population.
Literature review was carried out in the Medline (PubMed), Cochrane, and Scientific Electronic Library Online (SciELO) databases with the descriptors "Cannabidiol" and "Epilepsy." The search was not limited by the date of publication, language, or study design. A total of 69 articles were included in the review.
The efficacy of CBD in treating epileptic seizures has been confirmed by randomized controlled trials for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The incidence of side effects reported in subjects of the studies is high. However, most studies indicate a good safety profile and tolerance to the drug, with most of the adverse effects being mild to moderate and transient.
There is no consensus on the release of CBD as a therapeutic tool by the drug regulatory agencies worldwide. However, the use of CBD is promising since it has presented satisfactory results in crisis control in well-designed studies. In addition, this drug has a good safety and tolerance profile. However, further studies with a long follow-up period are needed to confirm its usefulness and the long-term safety in pediatric patients.
本研究旨在对大麻二酚（CBD）在儿科难治性癫痫治疗中的应用进行批判性评价。
在 Medline（PubMed）、Cochrane 和 Scientific Electronic Library Online（SciELO）数据库中，使用“大麻二酚”和“癫痫”这两个主题词进行文献检索。检索未对发表日期、语言或研究设计进行限制。共纳入 69 篇文献进行综述。
CBD 治疗 Lennox-Gastaut 综合征、Dravet 综合征和结节性硬化症的随机对照试验已经证实了其对癫痫发作的疗效。研究对象报告的副作用发生率较高。然而，大多数研究表明该药物具有良好的安全性和耐受性，大多数不良反应为轻度至中度且为一过性。
全球药物监管机构尚未就 CBD 作为治疗工具的发布达成共识。然而，鉴于 CBD 在设计良好的研究中对危机控制具有令人满意的效果，其应用前景广阔。此外，该药物具有良好的安全性和耐受性。然而，仍需要进行具有长期随访的进一步研究，以确认其在儿科患者中的有效性和长期安全性。
